Cross-sectional study shows dapagliflozin combinations improve glycemic control in type 2 diabetes, suggesting enhanced outcomes may address economic challenges.
Objective: To evaluate clinicians’ perspectives on the prevalence, contributing factors, and management strategies for uncontrolled type 2 diabetes mellitus (T2DM), with a focus on the use of dapagliflozin-based fixed-dose combinations (FDCs) in the Indian setting. Methodology: The cross-sectional study employed 23 questions focusing on clinicians’ views regarding uncontrolled T2DM and the role of dapagliflozin-based FDCs in improving glycemic, cardiovascular, and renal outcomes. Data analysis was conducted using the descriptive statistics. Results: The survey included responses from 464 clinicians. A significant proportion (89.01%) identified multiple contributing factors to uncontrolled T2DM, such as lack of physical activity, poor medication adherence, and irregular follow-ups, often influenced by economic challenges. The vast majority (93.75%) emphasized the importance of regular counseling, follow-up, and periodic glycemic monitoring. Nearly 65% of clinicians preferred combining a dipeptidyl peptidase-4 inhibitor with dapagliflozin. Around 84% recognized that the vildagliptin + dapagliflozin FDC offers multiple benefits, including improved glycemic control, reduced cardiovascular and renal risks, and enhanced adherence. Approximately 46% of the experts highlighted the complementary mechanism and glycemic efficacy of the glimepiride + metformin + dapagliflozin combination, with 74% favoring metformin 500 mg ER. About 41% of clinicians observed a 1–2 kg weight reduction, while 49% noted a 5–7 mmHg reduction in systolic blood pressure (SBP) with dapagliflozin-based FDCs. Conclusion: The survey findings underscore the key challenges such as poor adherence and economic limitations in T2DM management. Clinicians favored dapagliflozin-based FDCs, especially with glimepiride and metformin, for their potential to achieve better glycemic control, promote weight loss, and offer cardiorenal protection.
No takes yet. Share an insight, caveat, or question.
Shantaram et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: